Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria Patients who satisfy all of the conditions listed below.~1. Patients with histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) except for transformed lymphoma on the basis of World Health Organization (WHO) histological classification (4th ed., 2008).~2. Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma cells.~3. Patient with recurrent or relapsed DLBCL after R-CHOP-like theraphy as the firstline therapy.~4. Patients with measurable lesions \>1.5 cm in major axes.~5. Patients who are expected to survive for at least 3 months.~6. Patients aged 20 or above at the time informed consent is obtained.~7. Patient with Performance Status (P.S.) 0-1.~8. Patients with adequately maintained organ function.~Exclusion Criteria The study subject should be excluded if any one of the following condition exists.~1. Patients who have been without treatment for less than 3 weeks after prior treatment.~2. Patients who can be candidates for autologous peripheral blood stem cell transplantation at the discretion of the investigator.~3. Patients who received adequate prior treatments and did not respond to any of them.~4. Patient who received prior chemotherapy 3 regimens or more.~5. Patients with central nervous system (CNS) involvement or patients with clinical symptoms suggestive of CNS involvement.~6. Patient with serious active infection.~7. Patient with serious complication.~8. Patient with complication or medical history of serious cardiac disease.~9. Patient with serious gastrointestinal symptoms.~10. Patient with malignant pleural effusion, pericardial effusion, or ascites retention.~11. Patients positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, or HIV antibody.~12. Patient with serious bleeding tendency.~13. Patient with a fever of 38.0°C or higher.~14. Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema.~15. Patients with active multiple primary cancer or patients with a history of other malignant cancer within the past 5 years, except for basal cell cancer of the skin, squamous cell cancer, or cervical cancer in situ.~16. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia.~17. Patient who received bendamustin hydrochloride in the past.~18. Patients who received cytokine preparation such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 2 weeks before the examination at registration for this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SyB L-0501 (Type: EXPERIMENTAL): The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete